使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Please stand by. Hello and welcome, ladies and gentlemen, to the third quarter of fiscal year 2023 earnings conference call for Apyx Medical Corporation. (Operator instructions) Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.
請稍候。各位女士、先生,大家好,歡迎參加 Apyx Medical Corporation 2023 會計年度第三季財報電話會議。(接線員指示)請注意,本次電話會議將被錄音,錄音將於稍後提供於公司網站以供重播。
Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements, that are based on the current expectations of management and involve inherent risks and uncertainties that can cause actual results to differ materially from those indicated, including without limitation, those identified in the Risk Factors section of our most recent annual report Form 10-K , our most recent 10-Q filings and the company's other filings with the Securities and Exchange Commission.
在開始之前,我想提醒各位,我們今天的發言以及對各位提問的回應可能包含前瞻性陳述。這些陳述係基於管理層目前的預期,並涉及固有風險與不確定性,可能導致實際結果與所示內容存在重大差異,包括但不限於我們最新年度報告 Form 10-K 的「風險因素」章節、我們最新的 10-Q 申報文件,以及公司向美國證券交易委員會提交的其他文件中所識別的風險。
Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise. This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP.
此等因素可能會不時在我們向 SEC 提交的文件中更新,相關文件可於我們網站查閱。除非因新資訊、未來事件或其他原因,我們不承擔公開更新或修訂前瞻性陳述之義務。本次電話會議亦將提及若干非依一般公認會計原則(GAAP)計算之財務衡量指標。
We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings release, earnings press release on the Investor Relations portion of our web.
我們通常將其稱為非 GAAP 財務衡量指標。上述非 GAAP 財務衡量指標與依 GAAP 計算並呈列之最可比衡量指標之調節表,已載於財報新聞稿,並可於我們網站投資人關係(Investor Relations)專區的財報新聞稿中取得。
I would now like to turn the call over to Mr. Charlie Goodwin, Apyx Medical's President and Chief Executive Officer. Please go ahead.
現在我想把電話交給 Apyx Medical 總裁兼執行長 Charlie Goodwin 先生。請開始。
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Thanks, operator, and welcome, everyone, to our third quarter of 2023 earnings call. I'm joined on today's call by our Chief Financial Officer, Tara Semb. Let me provide you with a brief outline of what we intend to cover today. I'll begin by discussing our third quarter revenue results, followed by an update on the operational progress our team has made during the third quarter and in recent months.
謝謝接線員,也歡迎各位參加我們 2023 年第三季財報電話會議。今天與我一同出席的還有我們的財務長 Tara Semb。先為各位簡要說明今天的議程:我將先討論第三季營收結果,接著更新我們團隊在第三季及近幾個月的營運進展。
Tara will discuss our financial results in detail along with our 2023 financial guidance, which we updated in our earnings release today. I'll then share some additional closing remarks before we open the call for questions.
Tara 將詳細說明我們的財務結果,以及我們在今日財報新聞稿中更新的 2023 年財務指引。之後我會補充一些結語,接著開放提問。
With that, let's begin with a review of our revenue results. In the third quarter, we achieved total revenue growth of 31% year over year to $12 million. Our total revenue growth was primarily fueled by sales of our advanced energy products which increased 39% year over year to $9.8 million, while sales of our OEM products increased 5% year over year to $2.1 million.
那麼,我們先從營收結果回顧開始。第三季我們的總營收年增 31%,達到 1,200 萬美元。我們的總營收成長主要來自先進能量產品(advanced energy products)的銷售,年增 39% 至 980 萬美元;而 OEM 產品銷售年增 5% 至 210 萬美元。
Looking at the year-over-year performance in our Advanced Energy segment, more closely of the $2.8 million of total Advanced Energy revenue growth that we delivered year over year. We were pleased to see notable contributions from both the US and international geographies.
更仔細看我們先進能量事業部的年對年表現:我們年對年帶來的先進能量營收總成長為 280 萬美元。我們很高興看到美國與國際市場皆有顯著貢獻。
Our Advanced Energy revenue performance was primarily fueled by growth in global sales of our generators, which increased nearly 70% year over year, along with double digit growth from our sales of handpieces. In the US Specifically, sales of our advanced energy products increased 31% year over year, driven by generator sales growth that exceeded 70%.
我們先進能量營收表現主要由全球發電機(generators)銷售成長所帶動,年增接近 70%,同時手持器(handpieces)銷售也有雙位數成長。就美國市場而言,我們先進能量產品銷售年增 31%,其中發電機銷售成長超過 70% 是主要動能。
Importantly, a significant majority of our US generators sales in the third quarter was driven by sales to new customers. This was driven by our continued effort to raise awareness of both the safety and efficacy of our Renuvion technology, as supported by our new FDA clearances as well as our next generation system, the Apyx One Console, which we launched at the beginning of this year.
重要的是,我們第三季在美國的發電機銷售中,絕大多數來自新客戶。這反映我們持續致力於提升市場對 Renuvion 技術安全性與有效性的認知;此一認知亦受到我們新取得的 FDA 核准(clearances)以及我們於今年年初推出的次世代系統 Apyx One Console 的支持。
In addition to sales of two new US customers, we saw important contributions from generator sales to our existing users as well as they took advantage of our program, enabling them to upgrade to the Apyx One Console at a discounted pricing by trading in their prior generation system. Our generator sales performance more than offset flattish performance in sales of our US handpieces. I'll discuss the factors that contributed to this performance in a minute.
除了新增兩家美國客戶的銷售外,我們也看到既有用戶的發電機採購帶來重要貢獻,因為他們利用我們的方案,以舊換新並以折扣價格升級至 Apyx One Console。我們的發電機銷售表現,足以抵消美國手持器銷售相對持平的表現。我稍後會說明造成此表現的因素。
With respect to international Advanced Energy sales, we saw generator sales growth of nearly 70% year over year, with sales of our handpieces increasing more than 40%. Our growth in international generator and handpiece sales was primarily fueled by strong contributions from sales to our distributors in Latin America, although we saw year-over-year growth in all our other major geographic regions as well.
就國際先進能量銷售而言,我們看到發電機銷售年增接近 70%,手持器銷售增加超過 40%。國際發電機與手持器銷售成長主要來自拉丁美洲經銷商的強勁貢獻,不過我們其他主要地理區域也都呈現年對年成長。
To recap our advanced energy growth in the third quarter of 39% year over year was due to balanced contributions from both our US and OUS markets and driven primarily by global sales of our advanced energy generators.
總結而言,第三季先進能量業務年增 39%,係由美國與美國以外(OUS)市場的均衡貢獻所帶動,並主要由全球先進能量發電機的銷售驅動。
With this as a backdrop, let me now take a few minutes to walk you through the third quarter revenue performance versus expectations. While we delivered strong revenue growth on a year-over-year basis, our total revenue in the third quarter was a little more than $3 million lower than the $15 million to $16 million range we expected, range of expectations we provided on our most recent earnings call.
在此背景下,我接下來用幾分鐘說明第三季營收表現相對於預期的差異。雖然我們年對年營收成長強勁,但第三季總營收比我們在上次財報電話會議所提供的 1,500 萬至 1,600 萬美元預期區間,低了略多於 300 萬美元。
This delta was driven by lower than expected sales of our advanced energy generators and handpieces, primarily in the US. We believe three primary factors contributed to the softer advanced energy performance relative to our expectations in the third quarter.
此差異主要來自先進能量發電機與手持器銷售低於預期,且主要發生在美國市場。我們認為有三項主要因素,導致第三季先進能量表現相較我們預期偏弱。
First, with respect to generator sales, the overall market for cosmetic surgery capital equipment proved to be weaker than our guidance had assumed. Specifically as we progressed through the third quarter, we saw more prospective surgeon customers, delaying capital equipment purchases, citing high interest rates and broader economic uncertainty.
第一,就發電機銷售而言,整體美容手術資本設備市場比我們指引所假設的更疲弱。具體而言,隨著第三季進行,我們看到更多潛在外科醫師客戶延後資本設備採購,並提及高利率與更廣泛的經濟不確定性。
Second, during the third quarter, we observed strong seasonality related to potential patients and some surgeons taking summer vacations. The seasonal slowness was more pronounced than the trends we observed in recent years, and we experienced primarily in August and early September.
第二,在第三季期間,我們觀察到因潛在病患以及部分外科醫師暑期休假而產生的明顯季節性。此季節性放緩比我們近年所觀察到的趨勢更為顯著,主要發生在 8 月與 9 月上旬。
This dynamic primarily impacted the sales of our handpieces with more potential patients on vacation and fewer seeking procedures. For surgeons experiencing slower than expected case volumes, it also proved another reason to take a wait-and-see approach to capital equipment purchasing.
此一動態主要影響手持器的銷售,因為更多潛在病患在度假、尋求療程的人數減少。對於病例量低於預期的外科醫師而言,這也成為其對資本設備採購採取觀望態度的另一個原因。
And third, our sales and marketing execution during the quarter ultimately did not meet our expectations. In response to these issues, we have taken proactive steps to help mitigate their future impact. Beginning in September, we introduced financing options for our potential surgeon customers to provide them with further financial flexibility. And subsequent to quarter end, we made several changes in our sales and marketing team.
第三,我們在本季的銷售與行銷執行最終未達到我們的預期。針對這些問題,我們已採取主動措施以降低其未來影響。自 9 月起,我們為潛在外科醫師客戶推出融資選項,以提供更大的財務彈性;並在季末之後,我們也對銷售與行銷團隊進行了數項調整。
We expect to see improving productivity from this reorganized team in '24 and beyond. Stepping back, while we are ultimately disappointed with the softer than expected sales performance in the quarter, we were pleased to see evidence that our recently secured 510-K clearances and our next generator system are resonating with the surgeon community.
我們預期這個重整後的團隊在 2024 年及之後將展現更佳的生產力。從更宏觀的角度來看,雖然我們對本季銷售表現低於預期感到失望,但我們很高興看到跡象顯示,我們近期取得的 510-K 核准以及我們的下一代發電機系統,正在外科醫師社群中產生共鳴。
And importantly, we completed the 31% year-over-year revenue growth in the third quarter with continued profitability improvements, reducing our net loss attributable to stockholders and our adjusted EBITDA by 20% and 21% year over year, respectively.
同時也很重要的是,我們在第三季達成 31% 的年對年營收成長之際,仍持續改善獲利能力:歸屬於股東的淨損失以及調整後 EBITDA 分別年減 20% 與 21%。
Turning to a brief discussion of our recent operational highlights, we continued our effort to raise awareness of our Renuvion technology and its benefits at both the surgeon and patient level.
接著簡要談談近期營運亮點:我們持續在外科醫師與病患兩個層面,推動提升市場對 Renuvion 技術及其效益的認知。
With respect to surgeons, we continue to capitalize on the progress made by our regulatory team in recent years, which enabled us to secure new 510-K clearances in April for aesthetic body contouring following liposuction. We continue to believe that with the latest 510-K clearance. Our Renuvion APR handpiece is now the only device on the market with this indication for use following liposuction.
就外科醫師而言,我們持續利用近年法規團隊所取得的進展,使我們得以在 4 月取得新的 510-K 核准,用於抽脂後的美學身體塑形。我們仍然相信,憑藉最新的 510-K 核准,我們的 Renuvion APR 手持器目前是市場上唯一具備此一「抽脂後使用」適應症(indication for use)的裝置。
During the third quarter, we continued to focus on educating potential new prospects on these developments, along with the extensive body of clinical and real-world evidence that has been established to support the safety and efficacy of our products for use in the cosmetic surgery procedures. In spite of the headwinds I discussed earlier, these developments have helped our team reengage with many new prospects, and we believe they will continue to benefit our growth.
在第三季期間,我們持續專注於向潛在新客戶宣導這些進展,以及已建立的龐大臨床與真實世界證據體系,用以支持我們產品在美容外科手術程序中使用的安全性與有效性。儘管面臨我先前提到的逆風,這些進展已協助我們的團隊重新與許多新潛在客戶建立互動,我們相信它們將持續有利於我們的成長。
And at the patient level, we continued to advance our direct to consumer brand awareness campaign through the introduction of new content, including before-and-after photos, patient video testimonials and other content leveraging the results achieved by actual patients. In addition to expanding our following and engagement on social media, we have begun to receive more incidental feedback from surgeons seeing patients coming in asking about our Renuvion technology.
在病患層面,我們持續透過推出新內容來推進我們的直接面向消費者(DTC)品牌知名度活動,包括術前術後照片、病患影片見證,以及其他運用實際病患所達成成果的內容。除了擴大我們在社群媒體上的追蹤者與互動之外,我們也開始收到更多來自外科醫師的零星回饋,表示有病患前來詢問我們的 Renuvion 技術。
In terms of new product initiatives. As I mentioned earlier, we remain pleased with the US market reception to our next-generation generator. The Apyx One Console, which was an important contributor to our generator sales growth in the quarter. In late July, we also commenced the limited market release of our new Renuvion micro handpiece after securing 510-K clearance in June.
就新產品計畫而言。如我先前所提到,我們仍對美國市場對我們下一代產生器的反應感到滿意。Apyx One Console 在本季對我們的產生器銷售成長做出了重要貢獻。7 月下旬,在 6 月取得 510-K 核准後,我們也開始對全新的 Renuvion 微型手持器進行有限市場上市。
Based on the feedback we have gathered to date, the surgeon customers that are participating in our limited market release appreciate the significantly smaller instrument shaft of our micro handpiece and the benefits it brings to cases where smaller profile handpiece can provide improved access to the target region and ultimately facilitate soft tissue contraction.
根據我們迄今蒐集到的回饋,參與我們有限市場上市的外科醫師客戶很欣賞我們微型手持器顯著更小的器械軸身,以及其在需要較小外形手持器以改善對目標區域的進入、並最終促進軟組織收縮之病例中所帶來的效益。
The feedback obtained during the limited market release has proved important insights to enhance our surgeon training and recommendation as we prepare to initiate our full commercial launch by year end. In addition to driving strong profitability improvements in the third quarter, we continued to enhance our balance sheet condition and financial flexibility.
在有限市場上市期間取得的回饋,已提供重要洞見,有助於我們在準備於年底前啟動全面商業上市之際,強化外科醫師訓練與建議。除了在第三季帶動強勁的獲利能力改善之外,我們也持續強化資產負債表狀況與財務彈性。
In August, we received the $8.1 million payment from the Internal Revenue Service for the cash tax refunds that they approved at the beginning of the year. And we were pleased to announce today that we negotiated and entered into a new 5-year agreement with Perceptive Advisors for a facility of up to $45 million in senior secured term loans. This agreement provided us with $37.5 million of proceeds at closing, approximately $11 million of which was used to satisfy all obligations under our prior credit agreement, as well as approximately $2.5 million of transaction fees and other expenses related to the transaction.
8 月,我們收到美國國稅局(Internal Revenue Service)支付的 810 萬美元款項,該款項係其於年初核准的現金退稅。我們也很高興在今天宣布,我們已與 Perceptive Advisors 協商並簽訂一項新的 5 年期協議,提供最高 4,500 萬美元的優先擔保定期貸款額度。該協議在交割時為我們提供 3,750 萬美元的資金,其中約 1,100 萬美元用於清償我們先前信貸協議下的所有義務,另約 250 萬美元用於本交易相關的交易費用及其他支出。
This new facility provides us with access to additional capital at more favorable terms overall than our prior agreement, significantly strengthening our balance sheet and enhancing our financial flexibility. With our recent profitability improvements in the third quarter, $22.1 million of cash on our balance sheet at the end of the quarter and the proceeds and additional borrowing capacity under our Perceptive credit agreement, we believe we have the requisite capital and financial flexibility to pursue our strategic growth initiatives while driving continued progress towards our longer-term goals of generating sustained profitability and strong free cash flow generation.
這項新融資安排使我們得以在整體條件較先前協議更有利的情況下取得額外資本,顯著強化我們的資產負債表並提升財務彈性。隨著我們第三季近期獲利能力的改善、截至季末資產負債表上 2,210 萬美元的現金,以及 Perceptive 信貸協議下的資金與額外借款額度,我們相信我們具備所需資本與財務彈性,以推動策略性成長計畫,同時持續朝向我們較長期目標邁進,即實現持續獲利能力與強勁自由現金流的產生。
Before I turn the call over to Tara, I'd like to discuss an important announcement we made in our earnings press release this morning. Specifically, we announced Tara's intention to leave the Company in order to pursue other opportunities. As we announced in our earnings press release, the Board of Directors initiated a formal search process that identified her successor. We expect to announce the formal appointment in the near future.
在我把電話會議交給 Tara 之前,我想談談我們今天早上在財報新聞稿中發布的一項重要公告。具體而言,我們宣布 Tara 有意離開公司以追求其他機會。正如我們在財報新聞稿中所宣布,董事會已啟動正式的遴選程序並確認其接任人選。我們預期將在不久的將來宣布正式任命。
In the interim, we appreciate Tara's commitment to continue in her position as Chief Financial Officer until her successor is formally appointed. Since joining Apyx Medical in January of 2019, Terra has been an important contributor to our growth as an organization. Her efforts have enabled us to develop a strong financial and accounting team and to improve our analytical and reporting process to support the business.
在此期間,我們感謝 Tara 承諾將持續擔任財務長一職,直到其接任者正式任命。自 2019 年 1 月加入 Apyx Medical 以來,Tara 一直是我們組織成長的重要貢獻者。她的努力使我們得以建立強健的財務與會計團隊,並改善我們的分析與報告流程以支援業務。
On behalf of the broader team, I'd like to take the opportunity on today's call to thank her for the important contribution she made while at Apyx Medical, and I look forward to her continued support amid them smooth transition.
我謹代表更廣泛的團隊,藉由今天的電話會議向她在 Apyx Medical 任職期間所做出的重要貢獻致謝,並期待在順利過渡期間持續獲得她的支持。
I'll now turn it over to Tara to review the third quarter financial results and 2023 guidance, which we updated in today's press release. Tara?
接下來我將把時間交給 Tara,請她回顧第三季財務結果以及 2023 年指引(我們已在今天的新聞稿中更新)。Tara?
Tara Semb - CFO
Tara Semb - CFO
Thanks, Charlie. It has been a privilege to serve as a member of the Apyx medical team and to help develop the organization during my time here. With the financial and operational progress we've made over the last four years and the depth of our financial and accounting teams. I truly believe that Apyx Medical is well positioned going forward.
謝謝你,Charlie。能夠成為 Apyx Medical 團隊的一員,並在我任職期間協助組織發展,是一項榮幸。憑藉我們過去四年在財務與營運方面取得的進展,以及我們財務與會計團隊的深度,我真心相信 Apyx Medical 未來已具備良好定位。
I would like to thank my colleagues at Apyx for their support and look forward to supporting a successful transition to the incoming CFO. Given that Charlie discussed our revenue results, I will then begin at the gross profit line. Unless noted otherwise, all references to third quarter financial results are on a GAAP and year-over-year basis.
我要感謝我在 Apyx 的同事們給予的支持,並期待支持新任財務長順利交接。鑑於 Charlie 已討論我們的營收結果,我將從毛利項目開始。除非另有說明,所有對第三季財務結果的提及均以 GAAP 基礎並以年對年比較為準。
Gross profit for the third quarter of 2023 increased $2.2 million or 39% to $8 million. Gross profit margin was 66.6% compared to 63.2% last year. The increase in our gross margin was driven primarily by changes in the sales mix between our two segments, with our Advanced Energy segment comprising a higher percentage of total sales and changes in the product mix within our Advanced Energy segment, offset partially by geographic mix within our Advanced Energy segment.
2023 年第三季毛利增加 220 萬美元(或 39%)至 800 萬美元。毛利率為 66.6%,相較去年為 63.2%。我們毛利率的提升主要由兩個因素驅動:我們兩個事業部門之間的銷售組合變化(先進能源事業部門占總銷售的比重提高),以及先進能源事業部門內的產品組合變化;部分被先進能源事業部門內的地理區域組合所抵銷。
As International sales comprised a higher percentage of total Advanced Energy sales. Operating expenses increased $1.1 million or 9% to $12.6 million. The increase in operating expenses was driven primarily by salaries and related costs, which increased $0.8 million or 21% largely due to increases in bonus expense and labor and benefits costs.
因為國際銷售占先進能源總銷售的比重提高。營業費用增加 110 萬美元(或 9%)至 1,260 萬美元。營業費用的增加主要由薪資及相關成本所驅動,該項增加 80 萬美元(或 21%),主要是由於獎金費用以及人力與福利成本上升。
Loss from operations decreased $1.1 million or 20% to $4.6 million. We are pleased with the strong operating leverage we demonstrated in the third quarter, despite the softer than expected revenue results. Total other expense net was $0.4 million compared to income of $37,000. The change was driven by an increase in net interest expense related to the outstanding debt obligations on our term loan in the third quarter of 2023 compared to no outstanding borrowings in the prior year period.
營業損失減少 110 萬美元(或 20%)至 460 萬美元。儘管營收結果低於預期,我們對第三季展現的強勁營運槓桿感到滿意。其他費用淨額合計為 40 萬美元,相較之下去年為 3.7 萬美元的收入。該變動係由淨利息費用增加所致,原因是 2023 年第三季我們定期貸款項下存在未償還的債務義務,而去年同期並無未償借款。
Income tax benefit was $0.3 million compared to income tax expense of $50,000 last year. Net loss attributable to stockholders decreased $1.1 million or 20% to $4.6 million, or $0.13 per share, compared to $5.8 million or $0.17 per share last year. Adjusted EBITDA loss decreased $0.8 million or 21% to $3.1 million compared to $3.9 million last year. As a reminder, we provided a detailed reconciliation from net loss attributable to stockholders to non-GAAP adjusted EBITDA loss in our earnings press release.
所得稅利益為 30 萬美元,相較去年所得稅費用為 5 萬美元。歸屬於股東的淨損失減少 110 萬美元(或 20%)至 460 萬美元,或每股 0.13 美元,相較去年為 580 萬美元,或每股 0.17 美元。調整後 EBITDA 損失減少 80 萬美元(或 21%)至 310 萬美元,相較去年為 390 萬美元。提醒一下,我們在財報新聞稿中提供了從歸屬於股東的淨損失到非 GAAP 調整後 EBITDA 損失的詳細調節表。
For the three months ended September 30, 2023, cash generated for operating activities was $3.7 million compared to cash used in operating activities of $5.4 million in the prior year period. The improvement was driven primarily by an increase in cash related to the receipt of payment from the Internal Revenue Service for cash tax refunds as well as our improvement in net loss. As of September 30, 2023, we had cash and cash equivalents of $22.1 million compared to $10.2 million as of December 31, 2022.
截至 2023 年 9 月 30 日止三個月,營運活動產生的現金為 370 萬美元,相較去年同期營運活動使用的現金為 540 萬美元。改善主要由現金增加所驅動,該增加與收到美國國稅局支付的現金退稅款項以及我們淨損失的改善有關。截至 2023 年 9 月 30 日,我們的現金及約當現金為 2,210 萬美元,相較 2022 年 12 月 31 日為 1,020 萬美元。
Turning to our review of our 2023 financial guidance, which we updated in our earnings press release today. For the 12 months ending December 31, 2023, we now expect total revenue in the range of $53 million to $54 million, representing growth of approximately 19% to 21%. This compares to our prior range of $59 million to $62 million or growth of 33% to 39%.
接著我們回顧 2023 年的財務指引,我們已在今日發布的財報新聞稿中更新。就截至 2023 年 12 月 31 日的 12 個月而言,我們目前預期總營收將落在 5,300 萬至 5,400 萬美元區間,約代表 19% 至 21% 的成長。相較之下,我們先前的區間為 5,900 萬至 6,200 萬美元,或成長 33% 至 39%。
Total advanced -- Our total revenue guidance assumes Advanced Energy revenue of $44.5 million to $45.5 million, representing an increase of 21% to 24%, which compares to our prior range of $51 million to $54 million. And OEM revenue of approximately $8.5 million, representing growth of approximately 10%, which compares to our prior expectation of approximately $8 million.
總 Advanced——我們的總營收指引假設 Advanced Energy 營收為 4,450 萬至 4,550 萬美元,代表 21% 至 24% 的增幅,對比我們先前的 5,100 萬至 5,400 萬美元區間;以及 OEM 營收約 850 萬美元,代表約 10% 的成長,對比我們先前約 800 萬美元的預期。
In terms of our profitability guidance for the full year 2023, we now expect net loss attributable to stockholders of approximately $16 million, compared to our prior expectation of approximately $10.5 million. The updated net loss guidance reflects our revised revenue and loss expectations for the second half of 2023, including approximately $2.6 million of other expenses related to our debt transactions and approximately $0.5 million of severance related to our CFO transition.
就 2023 全年獲利能力指引而言,我們目前預期歸屬於股東的淨損約 1,600 萬美元,先前預期約為 1,050 萬美元。更新後的淨損指引反映我們對 2023 年下半年修正後的營收與虧損預期,其中包括約 260 萬美元與債務交易相關的其他費用,以及約 50 萬美元與 CFO 交接相關的資遣費用。
Our formal financial guidance for 2023 incorporates the following consideration for modeling purposes. First, we expect gross margins of approximately 66% compared to the prior guidance range of 66.5% to 67.5%. Second, we now expect 2023 operating expenses to decrease approximately 4% year over year compared to our prior guidance of low to mid, single digit growth year over year. No excluding the gain on our sale leaseback transaction, GAAP operating expenses are expected to be up 1% year over year in 2023.
我們 2023 年的正式財務指引納入以下供建模之考量。第一,我們預期毛利率約為 66%,相較先前指引區間 66.5% 至 67.5%。第二,我們目前預期 2023 年營業費用將較去年同期下降約 4%,相較先前指引為年增低至中個位數百分比。若不排除我們售後回租交易的收益,2023 年 GAAP 營業費用預期將較去年同期增加 1%。
Third, we expect total other expense net of approximately $3.6 million in 2023 compared to our prior guidance of approximately $900,000. The increase is driven by $2.6 million of nonrecurring fees and expenses incurred as part of our debt transactions. Note, we continue to expect interest expense net of approximately $1.6 million for 2023.
第三,我們預期 2023 年其他費用淨額合計約 360 萬美元,對比先前指引約 90 萬美元。增加主要來自我們債務交易所產生的 260 萬美元一次性費用與支出。請注意,我們仍預期 2023 年利息費用淨額約 160 萬美元。
And lastly, our guidance for 2023 now assumes noncontrolling interest of approximately $160,000 compared to $180,000 previously. An income tax benefit of approximately $2.4 million versus $2 million previously. Non-cash depreciation and amortization of approximately $0.7 million, unchanged versus our prior assumptions. Non-cash stock-based compensation expense of approximately $5.5 million versus $5.6 million previously. And weighted average diluted shares outstanding of approximately 34.7 million shares.
最後,我們對 2023 年的指引目前假設非控制權益約 16 萬美元,先前為 18 萬美元;所得稅利益約 240 萬美元,先前為 200 萬美元;非現金折舊與攤銷約 70 萬美元,與先前假設一致;非現金股份基礎給付費用約 550 萬美元,先前為 560 萬美元;以及加權平均稀釋後流通在外股數約 3,470 萬股。
Lastly, our updated guidance for 2023 now implies approximately $39 million in cash and cash equivalents on our balance sheet at December 31, 2023. Compared to our prior guidance of approximately $20 million. The updated target reflects the $24 million of net proceeds from our debt transactions and our revised net loss and cash flow assumptions based on our third quarter results and updated expectations for the fourth quarter.
最後,我們更新後的 2023 年指引目前意味著截至 2023 年 12 月 31 日,我們資產負債表上的現金及約當現金約為 3,900 萬美元,對比先前指引約 2,000 萬美元。更新後的目標反映我們債務交易取得的 2,400 萬美元淨收益,以及基於第三季結果與對第四季更新預期所修正的淨損與現金流假設。
With that, I'll turn the call back to Charlie for closing remarks.
接下來,我把電話交回 Charlie 作結語。
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Thanks, Tara. As Tara mentioned, our updated guidance reflects both our performance in the third quarter as well as our revised expectations for the balance of the year. Specifically, our 2023 revenue guidance implies Advanced Energy sales growth in the fourth quarter of 26% to 35% year over year, which contemplates the following assumptions.
謝謝,Tara。如 Tara 所提到的,我們更新後的指引反映了第三季的表現以及我們對今年剩餘期間的修正預期。具體而言,我們 2023 年營收指引意味著 Advanced Energy 第四季銷售額年增 26% 至 35%,其中包含以下假設。
The impact of the strategic reorganization of our sales and marketing team during the fourth quarter, we expect surgeons will remain reticent to purchase cosmetic surgery capital equipment, given the continued concerns related to the current financing environment and broader macro-economic uncertainty. And lastly, our guidance assumes sequential improvements in procedure volumes in the fourth quarter.
第四季我們銷售與行銷團隊策略性重整的影響;鑑於目前融資環境以及更廣泛的總體經濟不確定性所帶來的持續疑慮,我們預期外科醫師在購買醫美手術資本設備方面仍將保持謹慎;最後,我們的指引假設第四季手術量將較前一季改善。
We are committed to achieving our updated guidance expectations by continuing to leverage the important progress made by our team in recent years, including our 510-K clearances for specific clinical indications, the development and US commercial introduction of our next-generation Apyx One Console and our recent efforts to raise awareness and educate all levels of cosmetic surgery market through our direct to consumer initiatives, along with programming at conferences and trade shows.
我們致力於達成更新後的指引預期,並將持續運用團隊近年來取得的重要進展,包括針對特定臨床適應症取得 510-K 核准、開發並在美國商業化導入我們新一代 Apyx One Console,以及近期透過面向消費者的直接行銷(direct to consumer)計畫、搭配會議與展會的活動,提升醫美手術市場各層級的認知並進行教育。
And lastly, from an operational standpoint, we remain focused on driving continued execution with respect to our remaining strategic initiatives for 2023 to improve our positioning longer term. These are bringing new technologies like our Renuvion micro handpiece to the market, expanding our portfolio of clinical evidence, and managing our expenses as we drive continued progress towards profitability.
最後,從營運角度來看,我們仍專注於推動 2023 年剩餘策略性計畫的持續落實,以改善我們的長期定位。這些包括將如 Renuvion 微型手持器等新技術推向市場、擴充我們的臨床證據組合,以及在持續朝獲利邁進的同時管理費用。
In closing after more than five years of dedication and exclusive focus on the cosmetic surgery market, we know our Renuvion technology represents true innovation that dresses the needs of surgeons and their patients for a range of applications where other technologies have fallen short. Surgeons who begin using our Renuvion technology immediately recognize its advantages.
總結而言,在超過五年的投入並專注於醫美手術市場之後,我們深知 Renuvion 技術代表真正的創新,能滿足外科醫師及其病患在多種應用上的需求,而其他技術在這些應用上往往未能達到預期。開始使用 Renuvion 技術的外科醫師會立刻認知到其優勢。
And importantly, this drives them to continue using this differentiated technology going forward. For loyalty and utilization, we see across our global customer base is perhaps best evidenced by the fact that revenue from sales of our handpiece pieces has represented more than half of the $42 million of Advanced Energy revenue that we generated during the trailing 12 months ending December 30.
更重要的是,這也促使他們在未來持續使用這項差異化技術。就忠誠度與使用率而言,我們在全球客戶基礎中所觀察到的情況,或許最能由以下事實佐證:在截至 12 月 30 日的過去 12 個月中,我們所創造的 4,200 萬美元 Advanced Energy 營收中,來自手持器(handpiece)銷售的營收占比超過一半。
With this in mind, despite recent near-term setbacks we remain confident in the well-established capabilities of our Renuvion technology in our ability to expand our share of the multi-billion-dollar global market that lies ahead of us by facilitating its adoption and utilization.
基於此,儘管近期短期遭遇挫折,我們仍對 Renuvion 技術已被充分驗證的能力,以及我們透過促進其採用與使用、進而擴大在未來數十億美元規模全球市場市占率的能力,保持信心。
I'd like to thank our team and distributor partners for their efforts and continued dedication as well as our customers and shareholders for their support. With that operator, let's now open the call for questions.
我要感謝我們的團隊與經銷合作夥伴的努力與持續投入,也感謝我們的客戶與股東的支持。那麼,接線員,現在請開放提問。
Operator
Operator
Thank you. (Operator instructions)
謝謝。(接線員指示)
Frank Takkinen, Lake Street Capital Markets.
Lake Street Capital Markets 的 Frank Takkinen。
Frank Takkinen - Analyst
Frank Takkinen - Analyst
Hey, thanks for taking the questions. I was hoping we could start with just the assumptions around Q4 and same with the detailed guidance, but still seems like a pretty good step up there. So maybe talk through how you're thinking the seasonality will play out in Q4. What's normal seasonality in Q4? And how do you think that could be different this year based on your learnings from the front half of this year? And how are you thinking about the Renuvion handpiece portion of the Apyx.
嗨,謝謝讓我提問。我希望我們可以先從第四季的假設開始,以及同樣針對更細的指引內容來談,但看起來仍是相當不錯的上調幅度。所以也許請談談你們如何看待第四季的季節性會如何展開。第四季正常的季節性是什麼?根據你們從今年上半年得到的經驗,你們認為今年可能會有哪些不同?另外,你們如何看待 Apyx 中 Renuvion 手持器的占比?
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Yeah, all right. Thanks, Frank. Our updated guidance implies AE revenue growth of 26% to 35% year over year in Q4. And importantly, we see no improvement in the capital purchasing environment as compared to Q3. So we would think that Q3 and Q4 from a capital purchasing environment would be the same.
好的,沒問題。謝謝你,Frank。我們更新後的指引意味著第四季 AE 營收年增 26% 至 35%。而且重要的是,相較於第三季,我們沒有看到資本設備採購環境有任何改善。因此我們認為,就資本採購環境而言,第三季與第四季會是相同的。
We see some sequential improvement in procedure volumes in handpiece sales compared to Q3 as Q4 is always typically much more procedures are done than the Q3 time period. And it also reflects the changes that we made in our sales and marketing team in the fourth quarter.
我們看到手術量在第四季相較第三季有一些逐季改善,帶動手持器銷售,因為第四季通常進行的手術量會比第三季期間多得多。同時這也反映了我們在第四季對銷售與行銷團隊所做的調整。
Frank Takkinen - Analyst
Frank Takkinen - Analyst
Okay. That's helpful. And then maybe talking a little bit about the new Perceptive line. Can you talk through any covenants we should be aware of if there are any there on that front that could come into effect later?
好的,這很有幫助。接著也許談一下新的 Perceptive 額度(line)。你能否說明是否有任何我們需要留意的契約條款(covenants),以及是否可能在之後生效?
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Yes. So look, we are very pleased to secure this new credit facility, and we've made a lot of regulatory financial and operational process in recent months, and that has put us in a different position than when we first took out the credit, the previous credit facility. And so we made this strategic position to our decision to pursue this new agreement. And some of the keys for it was we wanted to obviously strengthen our balance sheet and we wanted it to provide us more financial flexibility as far as the covenants go on those.
是的。所以你看,我們非常高興能取得這項新的信貸融資額度;而且在過去幾個月裡,我們在監管、財務與營運流程方面做了大量工作,這使我們相較於當初取得上一個信貸融資額度時,處於不同的位置。因此,我們基於這樣的策略定位,決定推進這項新協議。其中幾個關鍵點是:我們顯然希望強化資產負債表,並希望就相關財務契約條款(covenants)而言,能為我們提供更大的財務彈性。
And so we were able to do both with this new agreement, the access to capital is up to $45 million, and it has more favorable financial flexibility terms overall. And with this new facility, we will be incredibly well capitalized to pursue our growth and value creation and will obviously 8-K the facility itself. So you'll get to see what all the different things are in that.
因此,我們透過這項新協議同時達成了這兩點:可動用資金最高達4,500萬美元,且整體而言具備更有利的財務彈性條款。透過這項新融資,我們將擁有非常充足的資本,以推動成長與價值創造;我們也會就該融資本身提交8-K。因此你將能看到其中所有不同的條款內容。
Frank Takkinen - Analyst
Frank Takkinen - Analyst
Okay. That's helpful. I'll stop there. Thanks.
好的。這很有幫助。我就先到這裡。謝謝。
Operator
Operator
Matthew O'Brien, Piper Sandler.
Matthew O'Brien,Piper Sandler。
Matthew O'Brien - Analyst
Matthew O'Brien - Analyst
Morning. Thanks for taking the questions. And Tara, best of luck to you in your future endeavours. Maybe just following up on that last question on Q4, Charlie, I'm looking at the model here and the bump that we're thinking about Q4 is a little steeper than we've seen historically. From Apyx, and we've got a tougher environment. So I'm just I'm just wondering what you're seeing so far in October and early November that give you that confidence in being the bigger step up and what's the more challenging macro environment?
早安。謝謝讓我提問。Tara,也祝你未來一切順利。延續剛才那個關於第四季的問題,Charlie,我在看模型時發現,我們對第四季的增幅預期比歷史上從Apyx看到的要更陡一些,而且目前環境也更具挑戰。所以我想問的是:你們在10月以及11月初目前看到哪些跡象,讓你們有信心認為會有更大的季增幅?以及在更具挑戰的總體環境下,你們的依據是什麼?
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Yeah. Look, I think that we're confident in our ability to deliver this for a few reasons. We've updated our guidance to reflect both the weaker environment of the capital equipment purchasing and the changes we've made to our organization in Q4 and now that we're on the summer months, we would expect sequential improvements in the procedure volumes and handpiece sales compared to compared to Q3.
是的。你看,我認為我們有幾個原因讓我們對交付這個目標有信心。我們已更新指引,以反映資本設備採購環境轉弱,以及我們在第四季對組織所做的調整;而且現在已經過了夏季月份,我們預期手術量與手柄(handpiece)銷售相較於第三季會有連續性的改善。
And we still see multiple tailwinds that we have as an organization. We've obviously got our new regulatory clearances and being the only company to have the clearance for body contouring procedures after liposuction is really resonating well with customers. We've still got obviously very good demand and very good momentum with our Apyx One generator, both through new customers here in the United States, but also on from upgrades.
此外,我們作為一個組織仍有多項順風因素。我們顯然已取得新的監管核准/許可;而且作為唯一一家在抽脂後身體塑形(body contouring)療程方面取得許可的公司,這點確實在客戶間引起很強的共鳴。我們的Apyx One主機(generator)仍然有非常好的需求與動能,不僅來自美國的新客戶,也來自既有客戶的升級需求。
And even though we believe that we can do a better job in our direct-to-consumer initiatives, we are starting to see fruition on that, where doctors are saying, patients are coming in and asking specifically for Renuvion. And so that's what gives us the confidence in our Q4 guide.
而且即便我們認為在直面消費者(direct-to-consumer)的推廣上還能做得更好,我們也開始看到成果:醫師表示,病患會進來並特別指名要Renuvion。這些就是讓我們對第四季指引有信心的原因。
Matthew O'Brien - Analyst
Matthew O'Brien - Analyst
Charlie, did you see that in October specifically?
Charlie,你在10月特別有看到這個現象嗎?
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
We won't comment necessarily on month by month when we're talking about, what we had, but the last two weeks of December were very strong from -- excuse me, from September were very strong from a demand perspective, and we have maintained a nice level of that sense.
我們在談這些時不會逐月評論具體情況;但從需求角度來看,9月最後兩週非常強勁——抱歉,是9月——而且我們也維持了不錯的水準。
Matthew O'Brien - Analyst
Matthew O'Brien - Analyst
Okay. I appreciate that. And then the follow-up question is just around the sales force adjustments. Can you be a little bit more specific on what you're doing there and then, you know, historically, as I've watched this space, you know, these sales force changes take some time to really get traction. So I guess what's the expectation here for Q4? And then what's the expectation in terms of the traction you'll get from these modifications in 2024?
好的,了解,謝謝。接著追問一下銷售團隊調整:你能否更具體說明你們在做什麼?另外,從我過去觀察這個領域來看,這類銷售團隊變動通常需要一些時間才能真正見到成效。所以我想問:你們對第四季的預期是什麼?以及這些調整在2024年預期會帶來什麼樣的成效與進展?
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Yes. Thanks, Matt. As I mentioned, our sales and marketing execution in the third quarter did not meet our expectations. And I want to be clear because I know I've got my commercial team that is listening to this. We had a great majority of our commercial team that was overachieving their expectations. And so I want to make sure that they know, and everybody knows that it is not the entire team, obviously.
是的,謝謝你,Matt。如我提到的,我們第三季在銷售與行銷的執行上未達到我們的預期。我想說清楚,因為我知道我們的商務團隊正在收聽:我們商務團隊中有絕大多數成員其實是超額達成預期的。因此我想確保他們知道、也讓大家知道,這顯然不是整個團隊的問題。
But on in response to the fourth quarter, we implemented strategic reorganizations in both sales and our marketing team, and our updated guidance contemplates the impact from this in Q4. But we believe, obviously that we've made the right changes to improve both areas of sales and marketing. And we're going to have be more productive from that group in the rest of this year, but also '24 in the long run, but our expectations are built into that change.
但針對第四季,我們在銷售與行銷團隊兩方面都實施了策略性的重整;我們更新後的指引也已納入這些調整在第四季的影響。不過我們顯然相信,我們做出了正確的改變,以改善銷售與行銷兩個面向。我們預期這個團隊在今年剩餘時間會更具生產力,長期來看在2024年也會如此;而我們的預期已反映在這些變更之中。
Matthew O'Brien - Analyst
Matthew O'Brien - Analyst
Understood. Thank you so much.
了解。非常感謝。
Operator
Operator
Matt Hewitt, Craig-Hallum.
Matt Hewitt,Craig-Hallum。
Matt Hewitt - Analyst
Matt Hewitt - Analyst
Good morning and thanks for taking the questions. Maybe first up on the international front, it sounds like you saw a rebound there. Do you feel like we've gotten past the safety communication issue and now it's more just a function of kind of introducing the platform to new customers and working with your distributors or is it still a little bit of kind of education, if you will, regarding the recent approval?
早安,謝謝讓我提問。先從國際市場談起,聽起來你們那邊有看到回升。你們覺得安全通報(safety communication)的議題已經過去了,現在更多只是把平台介紹給新客戶、並與經銷商合作的問題?還是說,針對近期核准仍需要一些教育推廣(如果可以這麼說)的工作?
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Yeah. No, it's a very good question. I think for the most part, we are past the safety notice for the most part. Obviously, it still comes up if people are going to Google and look at the company. So it is always something that we'll have to answer, but we have equipped our reps, our distributors and everybody else on obviously how to handle that, how to talk through that.
是的,這是個很好的問題。我認為就大部分而言,我們已經走過安全通知的影響。當然,如果有人去Google搜尋並查看公司資訊,這件事仍可能被提起,所以這始終是我們需要回應的議題;但我們已讓業務代表、經銷商以及其他所有相關人員都具備應對方式,知道該如何處理、如何說明。
And then just a tremendous amount of clinical data that we have to support that obviously helps that. And then the real kicker is, to have the indications that we have now and to get those final indications in the middle of this year has been a huge challenge, because obviously now the FDA is saying that these that this technology is safe and effective and specifically for these body contouring procedures.
另外,我們擁有大量臨床數據作為支持,這顯然也很有幫助。而真正的關鍵在於:我們現在擁有的適應症(indications),以及在今年年中取得最終適應症,這帶來了巨大的助力,因為FDA現在等於是在說,這項技術是安全且有效的,而且是特別針對這些身體塑形療程。
So we're very well equipped to be able to handle that as and if it does come up. But for the most part, we've moved past that and we're focused on how we make sure that we get more customers that get to see the benefits of Renuvion for their patients.
因此,若這個議題被提起,我們已經非常有能力去應對。但就大多數情況而言,我們已經走過那段影響期,現在重點是如何確保有更多客戶能看到Renuvion為其病患帶來的效益。
Matt Hewitt - Analyst
Matt Hewitt - Analyst
That's great. And then separately, maybe any initial feedback on the micro handpieces following your soft launch this past quarter, what are you hearing from the practices that are using it, is this something that you expect to ramp quickly upon the full launch? Thank you.
很好。另外,關於你們在本季進行軟性上市(soft launch)的微型手柄(micro handpieces),是否有任何初步回饋?你們從正在使用的診所那邊聽到什麼?在正式上市後,你們是否預期它會快速放量?謝謝。
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Yeah. So the micro handpiece has been having great reviews by our doctors that are using it. We're in the final stages right now of developing the protocols for some of the specific areas. And probably the three specific areas where we're seeing the most success with the micro handpiece are obviously the face, which that's not a surprise, we talked about that before, but also the hands and the labia are also areas where they're getting very good results with the micro handpiece.
是的。使用微型手柄的醫師給了非常好的評價。我們目前正處於為某些特定部位制定操作流程(protocols)的最後階段。大概有三個部位是我們看到微型手柄最成功的:顯然是臉部——這不令人意外,我們之前也談過——另外手部與陰唇(labia)也是他們使用微型手柄取得非常好效果的部位。
And so like I said, we're working through with our clinical team to work through the training, and we would expect that the micro handpiece would we have material contribution sometime next year.
因此,如我所說,我們正與臨床團隊一起推進訓練內容;我們預期微型手柄會在明年某個時點帶來實質性的貢獻。
Matt Hewitt - Analyst
Matt Hewitt - Analyst
Excellent. Thank you.
太好了,謝謝。
Operator
Operator
Thank you. (Operator instructions)
謝謝。(接線員指示)
George Sellers, Stephens.
George Sellers,Stephens。
George Sellers - Analyst
George Sellers - Analyst
Hey, good morning and thanks for taking the question. Maybe to start with the domestic market. I'm just curious if you could give some additional detail on the split between, Legacy device placements, and Apyx One device placement or how many of the new sales in the US in the quarter. What were Apyx One? And then also how many or where are you in rolling out the Apyx One to some of your legacy customers that are still using the legacy device?
嗨,早安,謝謝讓我提問。先從美國國內市場開始。我想請教你們是否能提供更多細節,說明本季在美國的新銷售中,傳統機型(Legacy)設備佈點與Apyx One設備佈點之間的分拆情況?也就是說,本季美國的新銷售中有多少是Apyx One?另外,你們在將Apyx One推廣給仍在使用傳統機型的既有客戶方面,目前進度到哪裡了?
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Yes. So we don't break down the actual numbers just to make sure that we're clear from Apyx ones and everything else. But the majority of our generator growth in the US was from sales to new customers.
是的。所以我們不會把實際數字再細分,主要是為了確保我們能清楚區分 Apyx One 的部分以及其他所有項目。不過,我們在美國的發電機(generator)成長大多來自於銷售給新客戶。
Okay. We did also have customers who took advantage of the upgrade program to the Apyx One and so, but the vast majority of growth that happened in that 70% growth in the US came from sales of new generators and the vast majority of those were Apyx ones that were sold.
好的。我們也確實有客戶利用升級方案升級到 Apyx One;但是,美國那 70% 成長中發生的絕大多數成長,來自於新發電機的銷售,而其中絕大多數是售出的 Apyx One。
George Sellers - Analyst
George Sellers - Analyst
Okay. That that's helpful.
好的。這很有幫助。
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Yep, sorry. No, that's it.
是的,抱歉。不,以上就是。
George Sellers - Analyst
George Sellers - Analyst
Okay. That's helpful. And then on the underlying market, have you seen any changes or shifts in how physicians are using this device? Any growth in standalone procedures or any changes in sort of the breakout between in conjunction with liposuction versus stand-alone skin tightening?
好的。這很有幫助。那麼在底層市場方面,你們有看到醫師使用這個設備的方式有任何變化或轉移嗎?單獨(standalone)療程是否有成長,或是在與抽脂合併使用(in conjunction with liposuction)相較於單獨皮膚緊緻(stand-alone skin tightening)之間的占比結構有任何變化?
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Yeah. No, it's a very good question. Yes, we have started to see evidence of them using Renuvion just as a standalone modality instead of following liposuction. And one of the big reasons for that is because of that some of the success that patients are having on these GLP-1 drugs, and they lose weight and then have black skin and so, obviously, and they're going to see plastic or cosmetic surgeons because I believe that they're going to be the greatest group that is going to benefit from the GLP-1 drugs over time.
有的。這是個非常好的問題。是的,我們已開始看到一些跡象:他們把 Renuvion 當作單獨的治療方式使用,而不是在抽脂之後才使用。其中一個很大的原因,是因為有些病患使用這些 GLP-1 藥物後很成功,體重下降後皮膚會變得鬆弛(原文為 black skin),所以很明顯他們會去看整形或醫美外科醫師;我相信長期來看,整形與醫美外科醫師會是最能從 GLP-1 藥物受益的一群。
But then obviously, if they've got locks or loose skin, there's not a better technology out there to address that minimally invasively than Renuvion. And so we are starting to see patients coming in with that issue and doctors being able to provide and a solution for them.
但很明顯,如果他們有鬆弛或皮膚下垂,市面上沒有比 Renuvion 更好的技術,能以微創方式來處理這個問題。因此我們開始看到病患帶著這個困擾前來,而醫師也能為他們提供解決方案。
George Sellers - Analyst
George Sellers - Analyst
Okay, great. Thanks for that color, and I'll leave it at just to thank you all for the time.
好的,很棒。謝謝你補充這些背景資訊;我就先到這裡,也謝謝大家撥冗。
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Thank you.
謝謝。
Operator
Operator
Thank you.
謝謝。
Dave Turkaly with JMP Securities.
JMP Securities 的 Dave Turkaly。
Dave Turkaly - Analyst
Dave Turkaly - Analyst
Hey, good morning. I just want to know, if you make share of your latest sort of market research on aesthetic procedures, just broadly what you're expecting sort of for the end of this year and into next year, recession or not like sort of how are the procedure volumes, what are you expecting? I guess even more specifically, what are you expecting for liposuction volume?
嗨,早安。我想了解一下,你們是否能分享最新的、關於醫美療程的市場研究?更廣泛地說,你們對今年年底到明年的預期是什麼?不論是否衰退,療程量(procedure volumes)你們預期如何?更具體一點,你們對抽脂(liposuction)量的預期是什麼?
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Yeah. So we expect, so the first thing is just the thing the market data doesn't change that quick as far as the research reports go. And so -- but we would expect over many, many years for body contouring procedures to expand and at a great rate, we saw liposuction in 2021 that grew 17% worldwide, and we would see that procedure and keep growing probably not at that kind of CAGR, but it will still have, I would say, a high single digit CAGR for a lot of years to come.
好的。我們的預期是——首先,市場數據就研究報告而言不會變得那麼快。所以——但我們預期在很多很多年內,體態雕塑(body contouring)療程會以很好的速度擴張。我們看到 2021 年抽脂在全球成長了 17%,我們也認為這個療程會持續成長,可能不會有那樣的年複合成長率(CAGR),但未來很多年仍會有我所說的高個位數 CAGR。
And when you look at the need that is going to be in the marketplace for all types of skin laxity, I think the procedure volumes are going to be huge on for many, many years to come in this and as I mentioned in the previous one, I think that plastic and cosmetic surgeons are going to be some of the bigger beneficiaries of these GLP-1 drugs because they create black skin when you lose weight and people have been trying to lose weight for years are now going to be motivated to go do something. And that go do something is to go see a plastic or a cosmetic surgeon.
而當你看到市場上對各種皮膚鬆弛(skin laxity)的需求,我認為未來很多很多年,相關療程量都會非常龐大。就像我在前一題提到的,我認為整形與醫美外科醫師會是這些 GLP-1 藥物較大的受益者之一,因為減重會造成皮膚鬆弛(原文為 black skin),而多年來一直想減重的人,現在會更有動力去做些什麼;而「做些什麼」就是去看整形或醫美外科醫師。
Dave Turkaly - Analyst
Dave Turkaly - Analyst
Thank you for the time.
謝謝你撥冗。
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Yeah.
好的。
Operator
Operator
Matt Hewitt with Craig-Hallum.
Craig-Hallum 的 Matt Hewitt。
Matt Hewitt - Analyst
Matt Hewitt - Analyst
Thank you for the follow up here. I just wanted to go back to something you said in your prepared remarks, Charlie, I think you said that revenues from sales of handpieces represented more than half of the $42 million in Advanced Energy generated during the trailing 12 months.
謝謝讓我追問。我想回到你在事先準備的發言中提到的一點,Charlie,我記得你說在過去 12 個月(trailing 12 months)內,手把(handpieces)銷售所帶來的營收,占 Advanced Energy 產生的 4,200 萬美元的一半以上。
Is it your expectation that, now that you've kind of crossed over on that median with the handpiece sales that that will continue to be the primary driver that, yes, you're obviously going to continue to sell the boxes, but now it's really about driving utilization and going forward. Thank you.
你是否預期,既然手把銷售已經跨過那個中位數門檻,未來它會持續成為主要驅動因素?也就是說,你們當然還會繼續賣主機(boxes),但接下來更重要的是推動使用量(utilization)。謝謝。
Charlie Goodwin - President & CEO
Charlie Goodwin - President & CEO
Yeah, no, thanks, Matt, and thanks for the question. Yeah, look, from quarter to quarter things could change based on the amount of capital that obviously we sell just from a math perspective. But what won't change is this the vast amount of our business that is from the consumables side of things and driving utilization, as you know, because you've been with the story for a while. We have spent a ton of time on evidence-based medicine and our clinical team helping drive utilization.
是的,謝謝你,Matt,也謝謝這個問題。你看,從單季到單季,因為我們資本設備(capital)的銷售量不同,從數學上來說數字可能會變動。但不會改變的是:我們業務的絕大部分來自耗材(consumables)端,以及推動使用量;如你所知,因為你跟這個故事很久了。我們在循證醫學(evidence-based medicine)上投入了大量時間,也透過臨床團隊協助推動使用量。
And one of the things that we are very fortunate to have is an incredible group of users that is incredibly passionate about the technology and they're passionate about the technology because of the results they're able to achieve with it for their patients. And as we keep bringing in more instruments and allowing them to treat more areas and they talk amongst themselves and figure out how we are using it and different areas and for different types of patients, whether it's life or patients or GLP-1 patients, that is going to keep driving that with that adoption and utilization of our handpieces.
而我們非常幸運的一點是,我們有一群非常出色的使用者,他們對這項技術充滿熱情;他們之所以熱情,是因為這項技術能為病患帶來他們能達成的效果。隨著我們持續推出更多器械,讓他們能治療更多部位,他們彼此交流、摸索我們如何使用它、用在哪些不同部位、以及針對不同類型的病患——不論是抽脂病患或 GLP-1 病患——這些都會持續推動手把的採用與使用量。
And that has always been a tremendous focus for us as an organization. We certainly do not want to be the company that is selling a piece of capital and having it sit in the doctor's office. For us, the focus is driving that utilization and partnering with the practice and allowing them to provide this great technology for their patients to give them these results. And so that has always been our focus and we will keep driving that number as high as we possibly can.
而這一直是我們組織的重大重點。我們當然不希望成為那種只賣出一台資本設備,結果它就放在醫師診所裡閒置的公司。對我們而言,重點是推動使用量,與診所合作,讓他們能把這項很棒的技術提供給病患、帶來這些效果。因此這一直是我們的重點,我們也會持續把這個數字推到我們所能達到的最高。
Matt Hewitt - Analyst
Matt Hewitt - Analyst
Great. Thank you.
很好,謝謝。
Operator
Operator
Thank you. We are currently showing no remaining questions at this time. With that, that does conclude our conference for today. Thank you for your participation. You may now disconnect.
謝謝。目前我們顯示沒有其他提問。那麼,今天的電話會議就到此結束。感謝各位的參與。您現在可以斷線。